Glück Conviction Score™ ⓘ
GILD
GILEAD SCIENCES, INC.
ⓘ
Eingeschränkte Aussagekraft — erst 64 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Stark
Sehr hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
75,0
230 neu, 833 erhöht, 7117,8M $ netto
Aktivist
49,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 132.97 | -5.5 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 129.16 | -2.8 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 129.11 | EMA50: 132.31 | |
| MACD-Histogramm | Bärisch | 10 % | -0.569 | Bearisch | |
| RSI(14) | Neutral | 10 % | 40.4 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 26.6 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 17.4 | +DI: 15.3 / −DI: 26.0 | |
| Z-Score(60) | Bullisch | 5 % | -1.76 | Extrem überverkauft | |
| 52W-Position | Neutral | 5 % | 39.4 % | Hoch 155.80 / Tief 105.93 | |
| Bollinger(20,2σ) | Neutral | 5 % | 20.1 % | Upper 136.83 / Mid 129.80 / Lower 122.76 | |
| LinReg-Slope(60) | Bärisch | 10 % | -0.2123 | R²=0.62 / annualisiert -40.0 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.062 | 132,22 | -404.842,64 | -34,1% | |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1.038 | 132,97 | -138.020,58 | -11,6% | |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.900 | 131,10 | -1.428.983,46 | -120,2% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -7.749 | 130,29 | -1.009.628,83 | -84,9% | |
| 2026-05-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 132,27 | -396.810,00 | -33,4% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -700 | 132,75 | -92.925,98 | -7,8% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -11.177 | 131,19 | -1.466.329,63 | -123,4% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -8.374 | 132,23 | -1.107.314,12 | -93,2% | |
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.950 | 128,79 | -895.074,52 | -75,3% | |
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.050 | 130,01 | -396.533,86 | -33,4% | |
| 2026-04-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3.000 | 140,96 | -422.880,00 | -35,6% | |
| 2026-04-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 140,96 | -422.880,00 | -35,6% | |
| 2026-03-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 136,82 | -1.368.162,00 | -115,1% | |
| 2026-03-16 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3.000 | 144,23 | -432.690,00 | -36,4% | |
| 2026-03-16 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 144,23 | -432.690,00 | -36,4% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.481 | 144,04 | -501.386,18 | -42,2% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.419 | 145,18 | -931.901,43 | -78,4% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -100 | 145,71 | -14.571,00 | -1,2% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -200 | 155,62 | -31.124,00 | -2,6% | |
| 2026-02-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 154,43 | -463.290,00 | -39,0% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -18.405 | 154,18 | -2.837.719,71 | -238,7% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -9.395 | 154,91 | -1.455.384,15 | -122,4% | |
| 2026-02-05 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115.640 | 150,00 | -17.346.000,00 | -1459,2% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -5.032 | 139,54 | -702.185,91 | -59,1% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -4.968 | 140,24 | -696.725,24 | -58,6% | |
| 2026-01-23 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115.640 | 135,00 | -15.611.400,00 | -1313,3% | |
| 2026-01-20 | Bluestone Jeffrey | Director | Open Market Sale | -5.000 | 123,50 | -617.500,00 | -51,9% | |
| 2026-01-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 124,31 | -372.930,00 | -31,4% | |
| 2026-01-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 124,31 | -372.930,00 | -31,4% | |
| 2025-12-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 124,83 | -1.248.272,00 | -105,0% | |
| 2025-12-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 122,00 | -366.000,00 | -30,8% | |
| 2025-12-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 122,00 | -366.000,00 | -30,8% | |
| 2025-11-28 | Bluestone Jeffrey | Director | Open Market Sale | -5.000 | 125,08 | -625.400,00 | -52,6% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.212 | 125,91 | -404.428,06 | -34,0% | |
| 2025-11-28 | Kramer Kelly A. | Director | Open Market Sale | -2.805 | 127,10 | -356.515,50 | -30,0% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.788 | 126,84 | -861.015,71 | -72,4% | |
| 2025-11-26 | Kramer Kelly A. | Director | Open Market Sale | -2.806 | 127,11 | -356.670,66 | -30,0% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -25.524 | 125,83 | -3.211.559,85 | -270,2% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2.476 | 126,26 | -312.613,57 | -26,3% | |
| 2025-11-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 125,23 | -313.075,00 | -26,3% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -500 | 122,90 | -61.452,00 | -5,2% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -35.965 | 122,30 | -4.398.591,43 | -370,0% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -17.181 | 124,00 | -2.130.444,00 | -179,2% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -7.978 | 119,54 | -953.666,98 | -80,2% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -2.022 | 118,82 | -240.258,69 | -20,2% | |
| 2025-10-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 118,08 | -354.240,00 | -29,8% | |
| 2025-10-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 118,08 | -295.200,00 | -24,8% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -8.039 | 111,47 | -896.109,74 | -75,4% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1.961 | 112,42 | -220.454,25 | -18,5% | |
| 2025-09-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 113,57 | -340.710,00 | -28,7% | |
| 2025-09-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 113,57 | -283.925,00 | -23,9% | |
| 2025-08-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 113,63 | -1.136.300,00 | -95,6% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -700 | 118,97 | -83.278,02 | -7,0% | |
| 2025-08-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 118,53 | -296.325,00 | -24,9% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11.800 | 118,51 | -1.398.405,02 | -117,6% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11.800 | 118,50 | -1.398.351,92 | -117,6% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2.800 | 118,51 | -331.820,72 | -27,9% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -200 | 118,97 | -23.793,00 | -2,0% | |
| 2025-07-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -8.345 | 114,09 | -952.076,88 | -80,1% | |
| 2025-07-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1.655 | 113,17 | -187.292,71 | -15,8% | |
| 2025-07-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 111,03 | -333.090,00 | -28,0% | |
| 2025-07-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 111,03 | -277.575,00 | -23,4% | |
| 2025-07-14 | Bluestone Jeffrey | Director | Open Market Sale | -5.000 | 109,74 | -548.700,00 | -46,2% | |
| 2025-06-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -9.400 | 110,40 | -1.037.795,72 | -87,3% | |
| 2025-06-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -600 | 111,15 | -66.688,02 | -5,6% | |
| 2025-06-16 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 110,17 | -275.425,00 | -23,2% | |
| 2025-06-16 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 110,17 | -330.510,00 | -27,8% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 119.010.973 | 123.195.578 | -4.184.605 | 16.586.559.275 | Reduziert | -3,4% | |
| VANGUARD GROUP INC | 121.097.336 | 0 | 121.097.336 | 14.863.487.020 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 80.654.776 | 0 | 80.654.776 | 11.240.856.131 | Neu | +100,0% | |
| FMR LLC | 71.906.290 | 65.579.490 | 6.326.800 | 10.021.579.771 | Aufgestockt | +9,6% | |
| STATE STREET CORP | 59.858.585 | 60.240.518 | -381.933 | 8.342.490.991 | Reduziert | -0,6% | |
| Capital World Investors | 41.283.933 | 42.872.129 | -1.588.196 | 5.753.020.069 | Reduziert | -3,7% | |
| GEODE CAPITAL MANAGEMENT, LLC | 29.726.052 | 29.696.002 | 30.050 | 4.135.590.576 | Aufgestockt | +0,1% | |
| Capital Research Global Investors | 27.127.533 | 25.307.071 | 1.820.462 | 3.780.727.903 | Aufgestockt | +7,2% | |
| DODGE & COX | 24.250.826 | 26.283.511 | -2.032.685 | 3.379.837.620 | Reduziert | -7,7% | |
| MORGAN STANLEY | 23.299.295 | 23.512.734 | -213.439 | 3.247.223.306 | Reduziert | -0,9% | |
| JPMORGAN CHASE & CO | 23.871.863 | 0 | 23.871.863 | 2.930.032.699 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 19.978.936 | 23.121.620 | -3.142.684 | 2.784.464.345 | Reduziert | -13,6% | |
| NORGES BANK | 21.322.732 | 0 | 21.322.732 | 2.617.152.126 | Neu | +100,0% | |
| Invesco Ltd. | 15.526.336 | 15.584.341 | -58.005 | 2.163.905.483 | Reduziert | -0,4% | |
| NORTHERN TRUST CORP | 13.820.379 | 14.057.956 | -237.577 | 1.926.146.221 | Reduziert | -1,7% | |
| WELLINGTON MANAGEMENT GROUP LLP | 13.537.991 | 15.907.304 | -2.369.313 | 1.886.789.807 | Reduziert | -14,9% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 13.199.103 | 13.000.814 | 198.289 | 1.839.558.986 | Aufgestockt | +1,5% | |
| GOLDMAN SACHS GROUP INC | 11.542.014 | 8.814.813 | 2.727.201 | 1.608.610.528 | Aufgestockt | +30,9% | |
| Amundi | 10.539.111 | 9.520.135 | 1.018.976 | 1.468.835.897 | Aufgestockt | +10,7% | |
| Legal & General Group Plc | 10.464.889 | 10.317.613 | 147.276 | 1.458.491.571 | Aufgestockt | +1,4% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8.181.780 | 8.006.790 | 174.990 | 1.140.294.679 | Aufgestockt | +2,2% | |
| Nuveen, LLC | 7.833.564 | 6.314.056 | 1.519.508 | 1.091.763.828 | Aufgestockt | +24,1% | |
| DIMENSIONAL FUND ADVISORS LP | 7.722.929 | 8.846.313 | -1.123.384 | 1.076.079.156 | Reduziert | -12,7% | |
| AMERIPRISE FINANCIAL INC | 7.287.230 | 7.800.418 | -513.188 | 1.015.799.153 | Reduziert | -6,6% | |
| WELLS FARGO & COMPANY/MN | 6.645.441 | 6.664.675 | -19.234 | 926.174.953 | Reduziert | -0,3% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 6.281.609 | 4.223.304 | 2.058.305 | 909.685.607 | Aufgestockt | +48,7% | |
| DEUTSCHE BANK AG\ | 6.222.328 | 6.193.754 | 28.574 | 867.205.853 | Aufgestockt | +0,5% | |
| CITADEL ADVISORS LLC | 6.063.685 | 6.057.220 | 6.465 | 845.095.779 | Aufgestockt | +0,1% | |
| ROYAL BANK OF CANADA | 5.865.522 | 6.340.381 | -474.859 | 817.478.000 | Reduziert | -7,5% | |
| BARCLAYS PLC | 5.836.796 | 9.650.083 | -3.813.287 | 813.474.259 | Reduziert | -39,5% | |
| NORDEA INVESTMENT MANAGEMENT AB | 5.260.363 | 5.138.699 | 121.664 | 726.613.942 | Aufgestockt | +2,4% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5.110.058 | 3.537.623 | 1.572.435 | 712.188.783 | Aufgestockt | +44,4% | |
| ALLIANCEBERNSTEIN L.P. | 5.729.225 | 5.896.300 | -167.075 | 703.205.077 | Reduziert | -2,8% | |
| BNP Paribas Asset Management Holding S.A. | 4.423.414 | 3.672.001 | 751.413 | 616.338.454 | Aufgestockt | +20,5% | |
| Boston Partners | 4.255.122 | 4.220.501 | 34.621 | 593.123.623 | Aufgestockt | +0,8% | |
| UBS Group AG | 4.144.104 | 5.358.067 | -1.213.963 | 577.563.774 | Reduziert | -22,7% | |
| AMERICAN CENTURY COMPANIES INC | 3.978.823 | 4.293.884 | -315.061 | 554.528.634 | Reduziert | -7,3% | |
| Swiss National Bank | 3.641.000 | 3.400.200 | 240.800 | 507.446.170 | Aufgestockt | +7,1% | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 3.584.898 | 3.701.656 | -116.758 | 499.627.234 | Reduziert | -3,2% | |
| BANK OF MONTREAL /CAN/ | 3.549.224 | 3.498.194 | 51.030 | 494.655.264 | Aufgestockt | +1,5% | |
| FRANKLIN RESOURCES INC | 3.484.026 | 3.295.546 | 188.480 | 485.568.473 | Aufgestockt | +5,7% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.447.111 | 3.559.632 | -112.521 | 480.424.000 | Reduziert | -3,2% | |
| TD ASSET MANAGEMENT INC | 3.372.079 | 3.357.740 | 14.339 | 469.966.650 | Aufgestockt | +0,4% | |
| Robeco Institutional Asset Management B.V. | 3.354.394 | 3.693.602 | -339.208 | 467.501.890 | Reduziert | -9,2% | |
| HSBC HOLDINGS PLC | 3.231.139 | 3.889.256 | -658.117 | 449.718.508 | Reduziert | -16,9% | |
| Allianz Asset Management GmbH | 3.218.527 | 4.145.430 | -926.903 | 448.566.108 | Reduziert | -22,4% | |
| FIRST TRUST ADVISORS LP | 3.129.637 | 1.446.051 | 1.683.586 | 436.177.491 | Aufgestockt | +116,4% | |
| VOYA INVESTMENT MANAGEMENT LLC | 3.052.813 | 2.747.594 | 305.219 | 425.470.599 | Aufgestockt | +11,1% | |
| National Pension Service | 3.021.468 | 2.990.660 | 30.808 | 421.101.995 | Aufgestockt | +1,0% | |
| Pacer Advisors, Inc. | 3.381.809 | 0 | 3.381.809 | 415.083.237 | Neu | +100,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 119.010.973 | 123.195.578 | -3,4% | 16.586.559.275 | 12,43 |
| VANGUARD CAPITAL MANAGEMENT LLC | 80.654.776 | 0 | +100,0% | 11.240.856.131 | 8,42 |
| FMR LLC | 71.906.290 | 65.579.490 | +9,6% | 10.021.579.771 | 7,51 |
| STATE STREET CORP | 59.858.585 | 60.240.518 | -0,6% | 8.342.490.991 | 6,25 |
| Capital World Investors | 41.283.933 | 42.872.129 | -3,7% | 5.753.020.069 | 4,31 |
| JPMORGAN CHASE & CO | 34.371.910 | 23.871.863 | +44,0% | 4.686.266.476 | 3,51 |
| GEODE CAPITAL MANAGEMENT, LLC | 29.726.052 | 29.696.002 | +0,1% | 4.135.590.576 | 3,10 |
| Capital Research Global Investors | 27.127.533 | 25.307.071 | +7,2% | 3.780.727.903 | 2,83 |
| DODGE & COX | 24.250.826 | 26.283.511 | -7,7% | 3.379.837.620 | 2,53 |
| MORGAN STANLEY | 23.299.295 | 23.512.734 | -0,9% | 3.247.223.306 | 2,43 |
| BANK OF AMERICA CORP /DE/ | 19.978.936 | 23.121.620 | -13,6% | 2.784.464.345 | 2,09 |
| Invesco Ltd. | 15.526.336 | 15.584.341 | -0,4% | 2.163.905.483 | 1,62 |
| NORTHERN TRUST CORP | 13.820.379 | 14.057.956 | -1,7% | 1.926.146.221 | 1,44 |
| WELLINGTON MANAGEMENT GROUP LLP | 13.537.991 | 15.907.304 | -14,9% | 1.886.789.807 | 1,41 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 13.199.103 | 13.000.814 | +1,5% | 1.839.558.986 | 1,38 |
| GOLDMAN SACHS GROUP INC | 11.542.014 | 8.814.813 | +30,9% | 1.608.610.528 | 1,21 |
| Amundi | 10.539.111 | 9.520.135 | +10,7% | 1.468.835.897 | 1,10 |
| Legal & General Group Plc | 10.464.889 | 10.317.613 | +1,4% | 1.458.491.571 | 1,09 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8.181.780 | 8.006.790 | +2,2% | 1.140.294.679 | 0,85 |
| Nuveen, LLC | 7.833.564 | 6.314.056 | +24,1% | 1.091.763.828 | 0,82 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 2.249 | 1.143,1 | 151.946 |
| 31.12.2025 | ✓ | 2.162 | 1.133,3 | 131.749 |
| 30.09.2025 | ✓ | 2.020 | 1.140,5 | 121.732 |
| 30.06.2025 | ✓ | 1.994 | 1.114,5 | 115.780 |
| 31.03.2025 | ✓ | 1.979 | 1.118,0 | 118.618 |
| 31.12.2024 | ✓ | 1.822 | 1.118,3 | 99.315 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NORGES BANK | 21.322.732 | 2.617.152.126 |
| Boston Partners | 4.220.501 | 517.808.259 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.559.632 | 436.909.000 |
| Eurizon Capital SGR S.p.A. | 956.470 | 117.430.237 |
| PFA Pension, Forsikringsaktieselskab | 826.930 | 101.861.255 |
| Alecta Tjanstepension Omsesidigt | 814.325 | 99.950.250 |
| CAXTON ASSOCIATES LLP | 550.000 | 67.507.000 |
| SOUTH PLAINS FINANCIAL, INC. | 418 | 51.304.000 |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 413.875 | 50.799.016 |
| Catalio Capital Management, LP | 289.312 | 35.510.155 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| BlackRock, Inc. | 123.195.578 | 6.914.187 | +5.9 % | 15.121.025.249 |
| FMR LLC | 65.579.490 | 5.263.211 | +8.7 % | 8.049.226.574 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 4.223.304 | 4.113.999 | +3763.8 % | 518.368.332 |
| BARCLAYS PLC | 9.650.083 | 3.942.335 | +69.1 % | 1.184.451.190 |
| BANK OF AMERICA CORP /DE/ | 23.121.620 | 2.865.488 | +14.1 % | 2.837.947.589 |
| JPMORGAN CHASE & CO | 23.871.863 | 2.189.628 | +10.1 % | 2.930.032.699 |
| VANGUARD GROUP INC | 121.097.336 | 2.113.692 | +1.8 % | 14.863.487.020 |
| BNP Paribas Asset Management Holding S.A. | 3.672.001 | 1.981.714 | +117.2 % | 450.767 |
| Amundi | 9.520.135 | 1.936.354 | +25.5 % | 1.168.501.370 |
| GOLDMAN SACHS GROUP INC | 8.814.813 | 1.651.011 | +23.0 % | 1.081.930.201 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 15.907.304 | -9.711.230 | -37.9 % | 1.952.462.494 |
| Capital Research Global Investors | 25.307.071 | -4.706.975 | -15.7 % | 3.106.193.871 |
| DODGE & COX | 26.283.511 | -3.849.620 | -12.8 % | 3.226.038.140 |
| Assenagon Asset Management S.A. | 267.054 | -3.222.008 | -92.3 % | 32.778.208 |
| DEUTSCHE BANK AG\ | 6.193.754 | -2.761.535 | -30.8 % | 760.221.365 |
| RENAISSANCE TECHNOLOGIES LLC | 2.788.728 | -2.674.016 | -49.0 % | 342.288.475 |
| Capital World Investors | 42.872.129 | -2.307.802 | -5.1 % | 5.262.268.432 |
| Qube Research & Technologies Ltd | 2.671.938 | -2.249.313 | -45.7 % | 327.953.670 |
| Allianz Asset Management GmbH | 4.145.430 | -1.730.589 | -29.5 % | 508.810.078 |
| FIRST TRUST ADVISORS LP | 1.446.051 | -1.643.232 | -53.2 % | 177.488.280 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 7,51 % | 93.327.127 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -8,97 pp | |
| 05.02.2026 | Abigail P. Johnson | Passiv (13G) | 5,30 % | 65.539.477 | Neu | |
| 05.02.2026 | FMR LLC | Passiv (13G) | 5,30 % | 65.539.477 | Neu | |
| 13.05.2025 | Capital World Investors | Passiv (13G/A) | 4,30 % | 53.834.873 | -2,40 pp | |
| 24.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 8,20 % | 101.739.273 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 8,97 % | 111.820.711 | +0,04 pp | |
| 09.02.2024 | Capital World Investors | Passiv (13G/A) | 6,70 % | 83.698.215 | +1,20 pp | |
| 24.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 9,90 % | 122.790.297 | -0,60 pp | |
| 13.02.2023 | Capital World Investors | Passiv (13G) | 5,50 % | 68.900.998 | Neu | |
| 13.02.2023 | Capital Research Global Investors | Passiv (13G/A) | 4,40 % | 54.602.952 | -4,10 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 8,93 % | 112.038.324 | +0,50 pp | |
| 31.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 10,50 % | 131.555.769 | +0,40 pp | |
| 08.07.2022 | . BlackRock, Inc. | Passiv (13G) | 10,10 % | 126.932.693 | +0,60 pp | |
| 11.02.2022 | Capital Research Global Investors | Passiv (13G/A) | 8,50 % | 107.156.981 | -1,20 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,43 % | 105.803.799 | +0,23 pp | |
| 01.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 9,50 % | 118.961.206 | +0,60 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 27.01.2026 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 23.09.2025 | Valerie Hoyle | – | House | Verkauf | $1,001 – $15,000 |
| 06.06.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 14.05.2025 | Josh Gottheimer | – | House | Verkauf | $1,001 – $15,000 |
| 12.05.2025 | Jefferson Shreve | – | House | Verkauf | $15,001 – $50,000 |
| 05.05.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 05.05.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 16.04.2025 | John Boozman | – | Senate | Verkauf | $1,001 – $15,000 |
| 31.03.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 10.03.2025 | Carol Devine Miller | – | House | Kauf | $1,001 – $15,000 |
| 07.03.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 24.12.2024 | Marjorie Taylor Mrs Greene | – | House | Kauf | $1,001 – $15,000 |
| 29.10.2024 | Valerie Hoyle | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Gilead Sciences, Inc., ein Biopharmaunternehmen, entdeckt, entwickelt und vermarktet Arzneimittel in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international. Das Unternehmen bietet Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild und Atripla zur Behandlung von HIV/AIDS; Veklury, ein Injektionspräparat zur intravenösen Anwendung zur Behandlung der Coronavirus-Krankheit 2019; und Epclusa, Harvoni, Vosevi, Vemlidy und Viread zur Behandlung von Lebererkrankungen. Es bietet auch Yescarta, Tecartus, Trodelvy und Zydelig zur Behandlung von Hämatologie-, Onkologie- und Zelltherapiepatienten. Darüber hinaus bietet das Unternehmen Letairis, ein Mundpräparat zur Behandlung der pulmonalen arteriellen Hypertonie; Ranexa, ein Mundpräparat zur Behandlung von chronischer Angina; und AmBisome, eine liposomale Formulierung zur Behandlung schwerwiegender invasiver Pilzinfektionen. Gilead Sciences, Inc. hat Kooperationsvereinbarungen mit Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; und Merck & Co, Inc. Das Unternehmen wurde 1987 gegründet und hat seinen Hauptsitz in Foster City, Kalifornien.
Unternehmen & Branche
| Name | GILEAD SCIENCES, INC. |
|---|---|
| Ticker | GILD |
| CIK | 0000882095 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 375558103 |
|---|---|
| ISIN | US3755581036 |
| Typ | Common Stock |
| Marktkapitalisierung | 150,76 Mrd. USD |
| KGV (P/E) | 17,92 |
| Beta | 0,31 |
| Dividendenrendite | 0,03 % |
Bewertung
| KBV (P/B) | 6,64 vs. 4,32 (2021) ▲ |
|---|---|
| KUV (P/S) | 5,12 vs. 3,33 (2021) ▲ |
| FCF-Rendite | 6,3 % vs. 11,9 % (2021) ▼ |
| Buyback-Rendite | 1,3 % vs. 0,6 % (2021) ▲ |
| Ausschüttungsquote | 47,0 % vs. 57,9 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 78,8 % vs. 75,8 % (2021) ▲ |
|---|---|
| Operative Marge | 34,0 % vs. 36,3 % (2021) ▼ |
| Nettomarge | 28,9 % vs. 22,8 % (2021) ▲ |
| ROIC | 17,6 % vs. 12,9 % (2021) ▲ |
| Zinsdeckungsgrad | 9,8 vs. 9,9 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 4,32 | 5,04 | 4,42 | 5,95 | 6,71 | |
| KUV (P/S) | 3,33 | 3,92 | 3,72 | 4,00 | 5,17 | |
| EV/EBITDA | 9,5 | 13,5 | – | – | – | |
| FCF-Rendite | 11,9 % | 7,8 % | 7,4 % | 9,0 % | 6,2 % | |
| Buyback-Rendite | 0,6 % | 1,3 % | 1,0 % | 1,0 % | 1,3 % | |
| Ausschüttungsquote | 57,9 % | 80,8 % | 67,2 % | 816,3 % | 47,0 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 75,8 % | 79,3 % | 76,0 % | 78,3 % | 78,8 % | |
| Operative Marge | 36,3 % | 26,9 % | 28,0 % | 5,8 % | 34,0 % | |
| Nettomarge | 22,8 % | 16,8 % | 20,9 % | 1,7 % | 28,9 % | |
| ROIC | 12,9 % | 9,8 % | 11,7 % | 1,0 % | 17,6 % | |
| Nettoverschuldung/EBITDA | 1,8 | 2,2 | – | – | – | |
| Zinsdeckungsgrad | 9,9 | 7,8 | 8,1 | 1,7 | 9,8 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 6.960.000.000 | 2.021.000.000 | 1,61 | 56.278.000.000 | 23.515.000.000 |
| 2025-12-31 | 10-K | 29.443.000.000 | 8.510.000.000 | 6,78 | 59.023.000.000 | 22.703.000.000 |
| 2025-09-30 | 10-Q | 7.769.000.000 | 3.052.000.000 | 2,43 | 58.533.000.000 | 21.540.000.000 |
| 2025-06-30 | 10-Q | 7.082.000.000 | 1.960.000.000 | 1,56 | 55.721.000.000 | 19.674.000.000 |
| 2025-03-31 | 10-Q | 6.667.000.000 | 1.315.000.000 | 1,04 | 56.434.000.000 | 19.162.000.000 |
| 2024-12-31 | 10-K | 28.754.000.000 | 480.000.000 | 0,38 | 58.995.000.000 | 19.330.000.000 |
| 2024-09-30 | 10-Q | 7.545.000.000 | 1.253.000.000 | 1,00 | 54.525.000.000 | 18.475.000.000 |
| 2024-06-30 | 10-Q | 6.954.000.000 | 1.614.000.000 | 1,29 | 53.579.000.000 | 18.281.000.000 |
| 2024-03-31 | 10-Q | 6.686.000.000 | -4.170.000.000 | -3,34 | 56.292.000.000 | 17.539.000.000 |
| 2023-12-31 | 10-K | 27.116.000.000 | 5.665.000.000 | 4,50 | 62.125.000.000 | 22.833.000.000 |
| 2023-09-30 | 10-Q | 7.051.000.000 | 2.180.000.000 | 1,73 | 62.373.000.000 | 22.314.000.000 |
| 2023-06-30 | 10-Q | 6.599.000.000 | 1.045.000.000 | 0,83 | 62.337.000.000 | 21.158.000.000 |
| 2023-03-31 | 10-Q | 6.352.000.000 | 1.010.000.000 | 0,80 | 61.876.000.000 | 20.997.000.000 |
| 2022-12-31 | 10-K | 27.281.000.000 | 4.592.000.000 | 3,64 | 63.171.000.000 | 21.240.000.000 |
| 2022-09-30 | 10-Q | 7.042.000.000 | 1.789.000.000 | 1,42 | 62.557.000.000 | 21.081.000.000 |
| 2022-06-30 | 10-Q | 6.260.000.000 | 1.144.000.000 | 0,91 | 62.870.000.000 | 20.236.000.000 |
| 2022-03-31 | 10-Q | 6.590.000.000 | 19.000.000 | 0,02 | 63.080.000.000 | 19.927.000.000 |
| 2021-12-31 | 10-K | 27.305.000.000 | 6.225.000.000 | 4,93 | 67.952.000.000 | 21.069.000.000 |
| 2021-09-30 | 10-Q | 7.421.000.000 | 2.592.000.000 | 2,05 | 67.098.000.000 | 21.470.000.000 |
| 2021-06-30 | 10-Q | 6.217.000.000 | 1.522.000.000 | 1,21 | 67.984.000.000 | 19.703.000.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 28,9 Mrd. | 28,6 Mrd. | 26,9 Mrd. | 27,0 Mrd. | 27,0 Mrd. | 32,8 % | +1,1% | |
| HIVProduct Sales | 20,8 Mrd. | 19,6 Mrd. | 18,2 Mrd. | 17,2 Mrd. | 16,3 Mrd. | 23,5 % | +5,8% | |
| HIVProducts Biktarvy | 14,3 Mrd. | 13,4 Mrd. | 11,9 Mrd. | 10,4 Mrd. | 8,6 Mrd. | 16,3 % | +6,8% | |
| Oncology Product | 3,2 Mrd. | 3,3 Mrd. | 2,9 Mrd. | 2,1 Mrd. | – | 3,7 % | -1,6% | |
| Liver Disease | 3,2 Mrd. | 3,0 Mrd. | 2,8 Mrd. | 2,8 Mrd. | – | 3,6 % | +6,5% | |
| HIVProducts Descovy | 2,8 Mrd. | 2,1 Mrd. | 2,0 Mrd. | 1,9 Mrd. | 1,7 Mrd. | 3,1 % | +30,5% | |
| Cell Therapy Products Total Cell Therapy Product Sales | 1,8 Mrd. | 2,0 Mrd. | 1,9 Mrd. | 1,5 Mrd. | 871,0 Mio. | 2,1 % | -6,8% | |
| HIVProducts Genvoya | 1,5 Mrd. | 1,8 Mrd. | 2,1 Mrd. | 2,4 Mrd. | 2,9 Mrd. | 1,7 % | -15,0% | |
| Other Products Yescarta | 1,5 Mrd. | 1,6 Mrd. | 1,5 Mrd. | 1,2 Mrd. | 695,0 Mio. | 1,7 % | -4,8% | |
| Trodelvy | 1,4 Mrd. | 1,3 Mrd. | 1,1 Mrd. | 680,0 Mio. | 380,0 Mio. | 1,6 % | +6,2% | |
| Liver Disease Products Sofosbuvir Velpatasvir | 1,3 Mrd. | 1,6 Mrd. | 1,5 Mrd. | 1,5 Mrd. | – | 1,4 % | -20,3% | |
| HIVProducts Odefsey | 1,2 Mrd. | 1,3 Mrd. | 1,4 Mrd. | 1,5 Mrd. | 1,6 Mrd. | 1,3 % | -9,4% | |
| Liver Disease Products Vemlidy | 1,1 Mrd. | 959,0 Mio. | 862,0 Mio. | 842,0 Mio. | – | 1,2 % | +11,6% | |
| Veklury | 911,0 Mio. | 1,8 Mrd. | 2,2 Mrd. | 3,9 Mrd. | 5,6 Mrd. | 1,0 % | -49,4% | |
| Liver Disease Products Other Liver Disease | 874,0 Mio. | 467,0 Mio. | 385,0 Mio. | 426,0 Mio. | – | 1,0 % | +87,2% | |
| Other Products Total Other Product Sales | 799,0 Mio. | 889,0 Mio. | 859,0 Mio. | 946,0 Mio. | 1,0 Mrd. | 0,9 % | -10,1% | |
| Royalty Contract And Other | 527,0 Mio. | 144,0 Mio. | 182,0 Mio. | 299,0 Mio. | 297,0 Mio. | 0,6 % | +266,0% | |
| Other Products Am Bisome | 509,0 Mio. | 533,0 Mio. | 492,0 Mio. | 497,0 Mio. | 540,0 Mio. | 0,6 % | -4,5% | |
| HIVProducts Other HIV | 500,0 Mio. | 434,0 Mio. | 401,0 Mio. | 530,0 Mio. | – | 0,6 % | +15,2% | |
| HIVProducts Symtuza Revenue Share | 495,0 Mio. | 592,0 Mio. | 529,0 Mio. | 530,0 Mio. | – | 0,6 % | -16,4% | |
| Cell Therapy Products Tecartus | 344,0 Mio. | 403,0 Mio. | 370,0 Mio. | 299,0 Mio. | 176,0 Mio. | 0,4 % | -14,6% | |
| Other Products Other | 290,0 Mio. | 356,0 Mio. | 367,0 Mio. | 449,0 Mio. | 209,0 Mio. | 0,3 % | -18,5% | |
| HCVProduct Sales | – | – | – | – | 1,9 Mrd. | – | – | |
| HCVProducts Sofosbuvir Velpatasvir | – | – | – | – | 1,5 Mrd. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product | – | – | – | – | 969,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Vemlidy | – | – | – | – | 814,0 Mio. | – | – | |
| Products Revenue Share Symtuza | – | – | – | – | 531,0 Mio. | – | – | |
| HIVProducts Truvada | – | – | – | – | 371,0 Mio. | – | – | |
| HIVProducts Complera Eviplera | – | – | – | – | 258,0 Mio. | – | – | |
| HCVProducts Ledipasvir Sofosbuvir | – | – | – | – | 212,0 Mio. | – | – | |
| Other HCV | – | – | – | – | 207,0 Mio. | – | – | |
| Other Products Letairis | – | – | – | – | 206,0 Mio. | – | – | |
| HIVProducts Stribild | – | – | – | – | 189,0 Mio. | – | – | |
| HIVProducts Atripla | – | – | – | – | 145,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Viread | – | – | – | – | 111,0 Mio. | – | – | |
| Other Products Zydelig | – | – | – | – | 62,0 Mio. | – | – | |
| Products Other HIV | – | – | – | – | 50,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Other | – | – | – | – | 44,0 Mio. | – | – | |
| Other Products Ranexa | – | – | – | – | 10,0 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 20,9 Mrd. | 20,6 Mrd. | 19,4 Mrd. | 18,9 Mrd. | 19,3 Mrd. | 70,9 % | +1,4% | |
| Europe | 5,1 Mrd. | 4,6 Mrd. | 4,3 Mrd. | 4,5 Mrd. | 4,9 Mrd. | 17,2 % | +9,3% | |
| Rest Of World | 3,5 Mrd. | 3,5 Mrd. | 3,4 Mrd. | 3,9 Mrd. | – | 11,9 % | -0,7% | |
| Other International | – | – | – | – | 3,2 Mrd. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 7,0 Mrd. USD | 1,61 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 7,8 Mrd. USD | 2,43 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 7,1 Mrd. USD | 1,56 |
| Q1 2025 | 31.03.2025 | 07.05.2026 | 6,7 Mrd. USD | 1,04 |
| Q3 2024 | 30.09.2024 | 07.11.2025 | 7,5 Mrd. USD | 1,00 |
| Q2 2024 | 30.06.2024 | 07.08.2025 | 7,0 Mrd. USD | 1,29 |
| Q1 2024 | 31.03.2024 | 07.05.2025 | 6,7 Mrd. USD | -3,34 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | 7,1 Mrd. USD | 1,73 |
| Q2 2023 | 30.06.2023 | 08.08.2024 | 6,6 Mrd. USD | 0,83 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | – | – | SEC » |
| 24.02.2026 | 10-K | 31.12.2025 | 55 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 23.02.2024 | 10-K | 31.12.2023 | 54 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 03.05.2023 | 10-Q | 31.03.2023 | 33 Tage | SEC » |
| 22.02.2023 | 10-K | 31.12.2022 | 53 Tage | SEC » |
| 02.11.2022 | 10-Q | 30.09.2022 | 33 Tage | SEC » |
| 08.08.2022 | 10-Q | 30.06.2022 | 39 Tage | SEC » |
| 04.05.2022 | 10-Q | 31.03.2022 | 34 Tage | SEC » |
| 23.02.2022 | 10-K | 31.12.2021 | 54 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 04.11.2020 | 10-Q | 30.09.2020 | 35 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 19.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 31.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.10.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 31.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-12 | 7.252 | 133,52 | 968.287 |
| 2026-05-11 | 21.146 | 131,33 | 2.777.104 |
| 2026-05-08 | 13.968 | 134,06 | 1.872.550 |
| 2026-05-07 | 976 | 136,30 | 133.029 |
| 2026-05-04 | 6.552 | 131,65 | 862.571 |
| 2026-04-29 | 2 | 129,26 | 259 |
| 2026-04-24 | 3.148 | 133,64 | 420.699 |
| 2026-04-20 | 400 | 137,64 | 55.056 |
| 2026-04-17 | 4 | 138,55 | 554 |
| 2026-04-15 | 11 | 140,45 | 1.545 |
| 2026-04-14 | 690 | 139,03 | 95.931 |
| 2026-04-10 | 644 | 142,09 | 91.506 |
| 2026-04-08 | 5 | 138,80 | 694 |
| 2026-04-07 | 41 | 140,13 | 5.745 |
| 2026-04-06 | 9.676 | 139,71 | 1.351.834 |
| 2026-04-02 | 43 | 140,30 | 6.033 |
| 2026-03-30 | 1 | 134,25 | 134 |
| 2026-03-25 | 124 | 138,11 | 17.126 |
| 2026-03-19 | 1 | 141,29 | 141 |
| 2026-03-13 | 1.887 | 145,21 | 274.011 |
| 2026-03-11 | 31.755 | 148,56 | 4.717.523 |
| 2026-03-06 | 544 | 145,14 | 78.956 |
| 2026-03-04 | 4.937 | 147,83 | 729.837 |
| 2026-03-03 | 127 | 150,03 | 19.054 |
| 2026-02-23 | 130.529 | 151,40 | 19.762.091 |
| 2026-02-20 | 9.977 | 151,12 | 1.507.724 |
| 2026-02-19 | 61 | 152,74 | 9.317 |
| 2026-02-18 | 100 | 155,27 | 15.527 |
| 2026-02-06 | 25.326 | 149,37 | 3.782.945 |
| 2026-02-02 | 300 | 141,95 | 42.585 |
| 2026-01-30 | 224 | 139,55 | 31.259 |
| 2026-01-26 | 1.600 | 135,93 | 217.488 |
| 2026-01-20 | 1.652 | 124,91 | 206.351 |
| 2026-01-15 | 1.031 | 124,07 | 127.916 |
| 2026-01-12 | 200 | 121,10 | 24.220 |
| 2026-01-08 | 80 | 124,35 | 9.948 |
| 2025-12-22 | 6.335 | 124,29 | 787.377 |
| 2025-12-19 | 6.856 | 121,47 | 832.798 |
| 2025-12-16 | 84 | 119,78 | 10.062 |
| 2025-12-15 | 500 | 120,40 | 60.200 |